Bayer’s Nubeqa scores key prostate cancer win in battle with Pfizer, J&J

Bayer and Orion’s Nubeqa may be late to the prostate cancer market, but new clinical data could give it a better chance at challenging Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Erleada—by making it the first among the three that can tout an overall survival win in the non-metastatic castration-resistant form of the disease.